RSCM
MREO

Rock Springs Capital Management’s Mereo BioPharma MREO Stock Holding History

Rock Springs Capital Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,570,649
Closed -$9.42M – 107
2025
Q3 		$9.42M Buy
4,570,649
+105,357
+2% +$194K 0.55% 53
2025
Q2 		$12.1M Sell
4,465,292
-2,218,955
-33% -$5.36M 0.75% 47
2025
Q1 		$15M Sell
6,684,247
-2,914,923
-30% -$8.25M 0.86% 43
2024
Q4 		$33.6M Buy
9,599,170
+65,000
+0.7% +$255K 1.28% 29
2024
Q3 		$39.2M Buy
9,534,170
+250,678
+3% +$1.04M 1.27% 29
2024
Q2 		$33.4M Buy
9,283,492
+1,141,383
+14% +$3.7M 1.01% 39
2024
Q1 		$26.9M Buy
8,142,109
+158,258
+2% +$536K 0.68% 51
2023
Q4 		$18.4M Buy
7,983,851
+307,370
+4% +$588K 0.45% 61
2023
Q3 		$9.9M Buy
7,676,481
+634,090
+9% +$841K 0.27% 73
2023
Q2 		$9.3M Buy
7,042,391
+797,494
+13% +$925K 0.22% 77
2023
Q1 		$4.41M Hold
6,244,897
– – 0.11% 92
2022
Q4 		$4.68M Hold
6,244,897
– – 0.11% 90
2022
Q3 		$5.38M Buy
6,244,897
+14,622
+0.2% +$17.9K 0.14% 93
2022
Q2 		$6.98M Buy
6,230,275
+155,332
+3% +$120K 0.2% 90
2022
Q1 		$6.8M Buy
6,074,943
+489,322
+9% +$633K 0.17% 96
2021
Q4 		$8.94M Buy
5,585,621
+752,643
+16% +$1.51M 0.21% 96
2021
Q3 		$11.7M Buy
4,832,978
+290,209
+6% +$768K 0.25% 100
2021
Q2 		$14.4M Buy
4,542,769
+47,900
+1% +$161K 0.28% 94
2021
Q1 		$15.1M Buy
+4,494,869
New +$15.9M 0.33% 84

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Rock Springs Capital Management's MREO Position: Q4 2025 in Review

Rock Springs Capital Management sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 4,570,649 shares — an estimated $9.42M sold.

Rock Springs Capital Management first reported a position in MREO in Q1 2021 and held it in 19 quarters. The position peaked at $39.2M in Q3 2024. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • Rock Springs Capital Management reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • Rock Springs Capital Management sold 4,570,649 Mereo BioPharma shares in Q4 2025, an estimated $9.42M.
  • Rock Springs Capital Management first reported a position in Mereo BioPharma in Q1 2021 and held it in 19 quarters.
  • Rock Springs Capital Management's Mereo BioPharma position peaked at $39.2M in Q3 2024.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Rock Springs Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.